FDA's Hamburg: Speed-up processing of generics

Share this article:

FDA commissioner Margaret Hamburg says it's taking the agency too long to approve generic drug applications and imposing user fees on generic drug companies could help speed the process. Company officials said they could accept fees if there are performance metrics to guarantee prompt action.

In a February speech to the Generic Pharmaceutical Association, Hamburg said the large backlog in generic drug applications “is a real problem. I don't pretend to believe that the status quo is acceptable.” Five years ago, FDA approved a new generic drug on average within 16.3 months of the filing. That time has increased to 26.7 months.
Hamburg said the slow-down stems not only from limited resources in the Office of Generic Drugs, but also from an increase in the number of applications in the last few years. In addition to recommending user fees, Hamburg said she would like to see a priority-setting system that would help FDA identify “the most critical drugs in terms of public health and patient access and move those more quickly.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?